LON:FBT

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Share Forecast, Price & News

GBX 1,505.80
-10.20 (-0.67 %)
(As of 06/15/2021 12:00 AM ET)
Add
Compare
Today's Range
1,505.80
1,521.20
50-Day Range
1,370.16
1,516
52-Week Range
1,357.60
1,765.40
Volume2,050 shs
Average Volume5,686 shs
Market Capitalization£4.45 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FBT News and Ratings via Email

Sign-up to receive the latest news and ratings for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation and its competitors with MarketBeat's FREE daily newsletter.


About First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation

Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content. The company operates under the brand name of Blackbird. The company was founded in 1998 and is based in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) Frequently Asked Questions

What stocks does MarketBeat like better than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation?

Wall Street analysts have given First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's key executives?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's management team includes the following people:
  • Mr. Ian McDonough, CEO & Director (Age 47)
  • Mr. Stephen B. Streater, Founder, Director of R&D and Exec. Director
  • Mr. Stephen James White, Chief Operating & Financial Officer and Director (Age 48)
  • Adrian Lambert, Marketing Director
  • Rachel Darcy, Sales Director

Who are some of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's key competitors?

What other stocks do shareholders of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation own?

Based on aggregate information from My MarketBeat watchlists, some companies that other First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation investors own include Taylor Wimpey (TW), ARK Genomic Revolution Multi-Sector ETF (ARKG), Johnson & Johnson (JNJ), Weyerhaeuser (WY), AbbVie (ABBV), ARK Innovation ETF (ARKK), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), Global X Robotics & Artificial Intelligence ETF (BOTZ) and Caterpillar (CAT).

What is First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's stock symbol?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation trades on the London Stock Exchange (LON) under the ticker symbol "FBT."

How do I buy shares of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation?

Shares of FBT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's stock price today?

One share of FBT stock can currently be purchased for approximately GBX 1,505.80.

How much money does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation make?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation has a market capitalization of £4.45 billion and generates £870,310.00 in revenue each year.

How many employees does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation have?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation employs 20 workers across the globe.

What is First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's official website?

The official website for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is www.forbidden.co.uk.

Where are First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's headquarters?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is headquartered at Tuition House, 27-37 St. Georges Road, LONDON, SW19 4EU, United Kingdom.

How can I contact First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's mailing address is Tuition House, 27-37 St. Georges Road, LONDON, SW19 4EU, United Kingdom. The company can be reached via phone at +44-20-88797245.


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.